Evidence map›Paper›PMID 37216160›Full record

ArticleOncology letters2023

Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or ref7ractory ALK+ anaplastic large cell lymphoma.

Yi Ding, Huina Lu, Yan Dong, Bing Xiu, Aibin Liang, Wenjun Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yi DingDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Huina LuDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Yan DongDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Bing XiuDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Aibin LiangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Wenjun ZhangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Tongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been reported that arsenic trioxide (ATO) regulates lymphoma cell cycle, apoptosis, autophagy and mitochondrial activity, while it synergizes with other cytotoxic agents. In addition, ATO targets anaplastic lymphoma kinase (ALK)-fusion oncoprotein to repress anaplastic large cell lymphoma (ALCL). The current study aimed to investigate the efficacy and safety of ATO plus etoposide, solumedrol, high-dose cytarabine and cisplatin (ESHAP) chemotherapy compared with ESHAP chemotherapy alone in patients with relapsed or refractory (R/R) ALK

Indexed as

anaplastic large cell lymphomaanaplastic lymphoma kinase positivearsenic trioxideESHAP chemotherapyrelapsed or refractory

Identifiers

PMID37216160
PMCPMC10193373
OpenAlexW4377565533

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.